Cargando…

How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy

Chimeric antigen receptor (CAR) T cells have transformed the care for patients with hematologic malignancies. Patients treated with CAR T cells may experience cardiovascular and pulmonary complications, which primarily occur in the setting of cytokine release syndrome. In addition, many patients con...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierrez, Cristina, Neilan, Tomas G., Grover, Natalie S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329189/
https://www.ncbi.nlm.nih.gov/pubmed/36827628
http://dx.doi.org/10.1182/blood.2022017579
_version_ 1785069968171204608
author Gutierrez, Cristina
Neilan, Tomas G.
Grover, Natalie S.
author_facet Gutierrez, Cristina
Neilan, Tomas G.
Grover, Natalie S.
author_sort Gutierrez, Cristina
collection PubMed
description Chimeric antigen receptor (CAR) T cells have transformed the care for patients with hematologic malignancies. Patients treated with CAR T cells may experience cardiovascular and pulmonary complications, which primarily occur in the setting of cytokine release syndrome. In addition, many patients considered for CAR T-cell therapy have preexisting cardiac and pulmonary comorbidities. Among patients with good functional status, these conditions should not prevent patients from being offered these lifesaving therapies. In this article, we use a case-based approach to discuss how we evaluate and optimize conditions for patients with cardiac and pulmonary risk factors before CAR T-cell therapy and manage cardiac and pulmonary complications that may arise with treatment.
format Online
Article
Text
id pubmed-10329189
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-103291892023-07-09 How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy Gutierrez, Cristina Neilan, Tomas G. Grover, Natalie S. Blood Emergent Car T-Cell Toxicities Chimeric antigen receptor (CAR) T cells have transformed the care for patients with hematologic malignancies. Patients treated with CAR T cells may experience cardiovascular and pulmonary complications, which primarily occur in the setting of cytokine release syndrome. In addition, many patients considered for CAR T-cell therapy have preexisting cardiac and pulmonary comorbidities. Among patients with good functional status, these conditions should not prevent patients from being offered these lifesaving therapies. In this article, we use a case-based approach to discuss how we evaluate and optimize conditions for patients with cardiac and pulmonary risk factors before CAR T-cell therapy and manage cardiac and pulmonary complications that may arise with treatment. The American Society of Hematology 2023-05-18 2023-02-28 /pmc/articles/PMC10329189/ /pubmed/36827628 http://dx.doi.org/10.1182/blood.2022017579 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Emergent Car T-Cell Toxicities
Gutierrez, Cristina
Neilan, Tomas G.
Grover, Natalie S.
How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy
title How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy
title_full How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy
title_fullStr How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy
title_full_unstemmed How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy
title_short How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy
title_sort how i approach optimization of patients at risk of cardiac and pulmonary complications after car t-cell therapy
topic Emergent Car T-Cell Toxicities
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329189/
https://www.ncbi.nlm.nih.gov/pubmed/36827628
http://dx.doi.org/10.1182/blood.2022017579
work_keys_str_mv AT gutierrezcristina howiapproachoptimizationofpatientsatriskofcardiacandpulmonarycomplicationsaftercartcelltherapy
AT neilantomasg howiapproachoptimizationofpatientsatriskofcardiacandpulmonarycomplicationsaftercartcelltherapy
AT grovernatalies howiapproachoptimizationofpatientsatriskofcardiacandpulmonarycomplicationsaftercartcelltherapy